CARTaGENE, Canada

Registration Status: Completed

Objective: CARTaGENE (CaG) is a biobank and a population-based cohort in Quebec, providing a unique resource with 43,000 participants representative of the population aged 40 to 69, followed prospectively. All data is accessible to the scientific community to accelerate health research. Recruitment was carried out in 2009-2010 and 2013-2014. The data collected includes questionnaires on health, nutrition, environment, physical measurements, etc. Biological samples (blood derivatives and urine) were collected to generate biochemical and genetic data. Data is regularly updated using health follow-up questionnaires and linkage to administrative health data. CaG is a public resource accessible to all health researchers.

Registered Biobank Name	CARTaGENE
Biobank Leader	Catherine Labbé
Country	Canada
Email for biobank inquiries	access@cartagene.qc.ca
Principal Investigator	Guillaume Lettre, Simon Gravel, Vikki Ho
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).